Navigation Links
OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
Date:11/14/2012

wed by electroporation. Concomitant therapy was permitted when warranted.

About NeoPulse

Surgical resection of skin cancers can pose significant challenges in achieving local control while preserving normal tissue and function without the risk of cosmetic damage. NeoPulse involves the combined use of electroporation with intratumoral injection of low-dose bleomycin to treat local tumors. An evaluation of the pharmacoeconomic benefits of NeoPulse therapy suggests it could afford healthcare savings in reducing the expense and complications of reconstructive surgery to address cosmesis.

About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking s
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec to Present at Upcoming Healthcare and Investor Conferences
2. OncoSec Granted New Patent from China
3. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
4. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
7. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
8. OncoSec Medical Issues Letter to Shareholders
9. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
10. Filtrona Porous Technologies Introduces New Medical-Grade Foams And Unique Fiber Products For Clean Environments At MEDICA / COMPAMED Trade Fair
11. Rochester Medical Reports Record Fourth Quarter and Fiscal Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 NxStage Medical, Inc. (Nasdaq: NXTM ... reported first quarter financial results that exceed the top ... for the first quarter of 2015 increased 10 percent ... for the first quarter of 2014. The Company,s revenue ... to $78.5 million.  The increase was driven by outperformance ...
(Date:5/6/2015)... , May 6, 2015  IGI Laboratories, Inc. (NYSE-MKT: IG), ... pharmaceutical company, will be presenting today at the Deutsche Bank ... on May 6 th and 7 th at ... Jason Grenfell-Gardner , CEO and President and ... will present today, May 6, 2015, at 3:30 p.m. ET.   ...
(Date:5/6/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ("Juniper" ... three-month period ended March 31, 2015. First quarter financial highlights ... increase of 19% as compared to $7.0 million in ... increased 41% year-over-year, enabled by the return of normalized ... in the fourth quarter of 2014; , Service ...
Breaking Medicine Technology:NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11
... Data presented yesterday showed that USL255, a novel ... less fluctuation in topiramate plasma levels than immediate-release ... These and other findings from the USL255 early ... the 64th annual American Epilepsy Society (AES) meeting ...
... Dec. 6, 2010 The Novartis Pharmaceutical Corporation ... disease control and tumor reduction in extensively pretreated ... become refractory after an autologous stem cell transplant, ... clinical trial presented today(1). In this ...
Cached Medicine Technology:Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 2Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 3Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7
(Date:5/6/2015)... Is Colorado’s legal cannabis industry the victim of ... will mark the 18-month milestone of its historic experiment ... Colorado’s legal marijuana industry has been successful and has ... some new challenges. , For example, many marijuana retailers ... the wake of last month’s “420” cannabis celebrations. And ...
(Date:5/6/2015)... 2015 Inversion Studios, a full-service ... and Pilates classes, provides personalized individual instruction and ... with its new Pilates Ring magic circle. , ... leaner, stronger, more centered and graceful, Inversion Studios ... venue to healthy fitness through yoga and Pilates. ...
(Date:5/6/2015)... Texas (PRWEB) May 06, 2015 vcfo, ... finance, HR, IT and operational support to optimize business ... Consulting CFOs, Jack Lynch and Michael Scheaffer. Both Lynch ... finance and leadership experience. , “We are delighted ... Ellen Wood, vcfo CEO. “Leveraging their background in financial ...
(Date:5/6/2015)... 2015 Wolters Kluwer , a ... students, announced today that in a survey of nearly ... of the clinical decision support resource improves the quality ... 2014, UpToDate users in more than 170 countries worldwide ... on average. In Germany alone, 95% of all university ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto ... of China, has successfully demonstrated a handheld real time ... Anitoa’s handheld qPCR is shown to be capable ... including hepatitis B, C, and E. Coli. This qPCR ... sample and over 9 orders of magnitude dynamic range. ...
Breaking Medicine News(10 mins):Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 3Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 2Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 3Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3
... NAPA, Calif., April 15 Senetek PLC (OTC,Bulletin Board: ... technologies that target the science of healthy aging, announced ... 2007., Revenue for the year ended December 31, ... for the fourth quarter of 2007,were $223,000, compared with ...
... 15 The Joint Center for,Political and Economic ... of health in order to reduce disparities and ... linked to,socioeconomic status," said Ralph B. Everett, the ... determinants, most health,inequities are avoidable," he added., ...
... a new study to evaluate the impact of a ... Presented at the American Association of Cancer Research Annual ... tracking system is key to improving rates of medical ... eliminating racial disparity in treatment. , Women who ...
... many with the autoimmune disease, researchers say , , TUESDAY, April ... the number of attacks in people with multiple sclerosis appears ... The pill was effective in preventing relapses in more than ... years, according to research that was expected to be presented ...
... Council (ACC) supports the rigorous scientific evaluation process,of ... Evaluation of,Risks to Human Reproduction. Following an expert ... NTP Brief on bisphenol A affirms that,there are ... effects of,bisphenol A on human reproduction and development., ...
... their names to ghost-written studies that exaggerated painkiller,s ... Industry documents reveal that pharmaceutical giant Merck & ... Vioxx research published in top medical journals while ... controversial cox-2 painkiller. , The company apparently also ...
Cached Medicine News:Health News:Senetek PLC Reports 2007 Financial Results 2Health News:Senetek PLC Reports 2007 Financial Results 3Health News:Joint Center Sees Social Determinants of Health as Key to Reducing Disparities at Annual Fund-raising Gala 2Health News:Tracking and feedback registry helps reduce disparities in breast cancer care 2Health News:Pill Reduces Relapses in MS Patients 2Health News:Draft National Toxicology Program Report Supports Safety of Bisphenol A 2Health News:Key Vioxx Research Was Written by Merck, Documents Allege 2Health News:Key Vioxx Research Was Written by Merck, Documents Allege 3Health News:Key Vioxx Research Was Written by Merck, Documents Allege 4
... of the benefits and functionality of ... additional feature of being able to ... for importing and storage of up ... This additional feature allows for complete ...
Inquire...
Inquire...
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field....
Medicine Products: